This study was conducted to compare the treatment efficacy between a prandial glucose regulator, repaglinide and a new sulphonylurea, glimepiride in Muslim Type 2 diabetic patients who practice Ramadan fasting. Forty-one patients, previously treated with a sulphonylurea or metformin, were divided to receive either repaglinide (n=20, preprandially three-times daily) or glimepiride (n=21, prepran...

R epaglinide is an insulin secretagogue with a rapid onset and short duration of action. Several studies have proposed repaglinide to be a safe and effective treatment for patients, including elderly people with type 2 diabetes (1–3). Here we report a case subject with type 2 diabetes who showed severe thrombocytopenia due to repaglinide. A 71-year-old man was referred and admitted to our hospi...

OBJECTIVE Repaglinide is a new oral hypoglycemic agent that acts as a prandial glucose regulator proposed for the treatment of type 2 diabetes by stimulating insulin secretion. The aim of this study was to explore actions of repaglinide on the rapid pulsatile insulin release by high-frequency insulin sampling and analysis of insulin-concentration time series. RESEARCH DESIGN AND METHODS We ex...

Objective: The present study’s is to develop floating drug delivery system of repaglinide. Methods: Moringa gum, Repaglinide, HPMC K100M, Sodium alginate, Calcium Carbonate, Citrate. obtained formulation was evaluated for content, pH, in vitro gelling capacity, buoyancy studies, and dissolution studies. Results Discussion: All the total F1-F12 formulations showed pH ranging from 5.1 7.9, lag ti...

This prospective, 1-year, multicenter, double-blind, randomized, parallel-group study was designed to show that repaglinide was at least equivalent to glyburide in patients with type 2 diabetes. Five hundred and seventy-six patients with type 2 diabetes of at least 6 months' duration were randomized to receive monotherapy with repaglinide (n = 383) or glyburide (n = 193). During weeks 1-8, dose...

OBJECTIVE Non-obese patients with type 2 diabetes (T2DM) are characterized by predominant defective insulin secretion. However, in non-obese T2DM patients, metformin, targeting insulin resistance, is non-inferior to the prandial insulin secretagogue, repaglinide, controlling overall glycaemia (HbA1c). Whether the same apply for postprandial glucose and lipid metabolism is unknown. Here, we comp...

AIMS/INTRODUCTION We investigated the efficacy and safety of repaglinide as an add-on therapy for Japanese patients with type 2 diabetes mellitus receiving metformin monotherapy (at a dose of 1,500 mg/day, mainly) in addition to diet and exercise. MATERIALS AND METHODS In the 16-week multicenter, placebo-controlled, randomized, double-blind, parallel-group trial (the phase III study), patient...

This report focuses on a 16-year-old girl afflicted with hypoglycemia after administration of medications for gastrointestinal symptoms. Repaglinide-induced hypoglycemia was suspected when a tablet of repaglinide was noted in the drug package that she had been given. As the use of various types of oral hypoglycemic agents has increased, a definitive diagnosis of drug-induced hypoglycemia has be...

One adverse effect of methylprednisolone (MP) pulse therapy is an acute dose-dependent increase in the blood glucose level. Five patients with thyroid ophthalmopathy but normal glucose tolerance received MP pulse therapy (3 cycles, 3 days/week) and were assessed by continuous glucose monitoring. Steroid therapy increased the mean sensor glucose level, and all patients developed steroid-induced ...

Meglitinides (repaglinide and nateglinide) are insulin secretagogues used to treat diabetes mellitus. We present a case of hypersensitivity reaction to repaglinide in a 61-year-old man who developed a maculopapular rash 5 days after treatment. Skin prick tests including repaglinide (0.5 g/mL) and patch tests (0.05% in pet and saline) were performed, and the results were negative. A blind oral c...